Jae Young Joung

Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final totale...

Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final totale overleving re...

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostat...

First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant...

Talazoparib plus enzalutamide bij mCRPC: TALAPRO-2 veiligheid

Olaparib bij mCRPC met HRR-alteraties: real-world analyse

Olaparib plus abiraterone versus placebo plus abiraterone bij mCRPC: PROpel fase III definitief

Talazoparib plus enzalutamide bij eerstelijns mCRPC: TALAPRO-2 fase III

Olaparib-verdraagzaamheid en bijwerkingenmanagement bij mCRPC: PROfound analyse

QoL met olaparib versus ARPI bij mCRPC: PROfound analyse